# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
"Mad Money" host Jim Cramer said, "Any time there's immunity-compromised patients, there's some big money d...
Key Findings from the Study:Overall Survival (OS): The study reported median OS of 22.4 months for patients treated with HEPZAT...
Delcath Systems, Inc. (NASDAQ:DCTH) ("Company" or "Delcath"), an interventional oncology company focused on the...
Stephens & Co. analyst Sudan Loganathan reiterates Delcath Systems (NASDAQ:DCTH) with a Overweight and maintains $25 pri...
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Delcath Systems (NASDAQ:DCTH) with a Buy and maintains $22...
Delcath Systems (NASDAQ:DCTH) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0...